Results 301 to 310 of about 368,214 (310)

The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy

Nature Reviews Cancer, 2008
Ludger Hengst, Joyce M Slingerland
exaly  

The evolving landscape of tissue‐agnostic therapies in precision oncology

Ca-A Cancer Journal for Clinicians
Vivek Subbiah, Bettina Ryll, Razelle Kurzrock   +2 more
exaly  

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

Nature Reviews Clinical Oncology, 2017
Mizuki Nishino, Hiroto Hatabu, F Stephen Hodi   +2 more
exaly  

Effect of Cathepsin K Inhibitor Basicity on in Vivo Off-Target Activities

Molecular Pharmacology, 2008
S. Desmarais, W. Black, R. Oballa, S. Lamontagne, D. Riendeau, P. Tawa, L. Duong, M. Pickarski, M. Percival   +8 more
semanticscholar   +1 more source

Interplay between β-lactamases and new β-lactamase inhibitors

Nature Reviews Microbiology, 2019
Karen Bush, Patricia A Bradford
exaly  

[Pharmacologic interest in HIV protease inhibitors: concepts and utilization].

Medecine et maladies infectieuses, 2007
openaire   +1 more source

Neither dapsone hydroxylation nor cortisol 6β-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors

European Journal of Clinical Pharmacology, 1998
R. J. A. Gass, J. Gal, P. W. Fogle, D. Detmar-Hanna, J. G. Gerber   +4 more
semanticscholar   +1 more source

The intracellular pharmacology of the antiretroviral protease inhibitors in a clinical setting

2004
openaire   +1 more source

SWITCH TO AROMATASE INHIBITOR BETTER THAN CONTINUING TAMOXIFEN

Ca-A Cancer Journal for Clinicians, 2005
exaly  

[Preparation of synthetic inhibitors of serine proteases--a pharmacological program of great significance].

Polskie Archiwum Medycyny Wewnetrznej, 1978
openaire   +1 more source